Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
SyntheX logo — Targeting the undruggable with synthetic biology-based drug...

SyntheX

Targeting the undruggable with synthetic biology-based drug discovery platforms

Founded 2016 United States San Francisco, United States 26 employees Series Unknown Total: $11.58M Biotechnology, Health and Wellness +2

General Information

Company Name SyntheX
Founded Year 2016
Location United States San Francisco, United States +1
Employees 26
Industries Biotechnology, Health and Wellness, Life Sciences +1
Funding Stage Series Unknown
Social

Get notified when SyntheX moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About SyntheX

SyntheX is a biotechnology and pharmaceutical startup founded in 2016 in the United States. The company's slogan "Targeting the undruggable with synthetic biology-based drug discovery platforms" encapsulates its focus on utilizing synthetic biology to revolutionize drug discovery. SyntheX's approach involves using genetically engineered circuits for intracellular drug selection, instead of traditional in-vitro screening, enabling the discovery of unbiased compounds with novel modes of action. Their proprietary technologies, including ToRPPIDO and ToRNeDO, are designed to identify disruptors of protein-protein interactions (PPIs) and functional molecular glues for degraders of a neosubstrate of interest with a desired E3 ligase. Additionally, the incorporation of DNA-encoded libraries of peptides and macrocycles allows for efficient and high-throughput production and selection of molecules. The last investment in SyntheX was a significant $5.18M Venture Round investment on December 29, 2023. The specifics of the investors in this round are not currently disclosed. SyntheX's primary focus is on oncology, positioning the company to make impactful contributions to cancer treatment and potentially disrupt the existing landscape of drug discovery in the field.

Taxonomy: Synthetic Biology, Drug Discovery, Oncology, Genetic Engineering, Protein-Protein Interactions, Targeted Protein Degradation, Cancer Genetics, Therapeutics, Synthetic Lethality, Biologics, Ras, Molecular Glues, Peptides, Functional Selection

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• - 29 Dec 2023
Corporate Round •••••• 1 •••• •••• 04 Oct 2022
Convertible Note •••••• 2
Investor Investor
27 Jul 2022
Convertible Note •••••• 2
Investor Investor
03 Sep 2020
Seed Round •••••• 4
Investor Investor Investor Investor
01 Mar 2017

View All 6 Funding Rounds

SyntheX Alternatives & Competitors

SyntheX vs
TRIANA Biomedicines
TRIANA Biomedicines

A venture-backed biopharmaceutical company dedicated to discovering and developing novel therapeutic...

SyntheX vs
A-Alpha Bio
A-Alpha Bio United States

The protein-protein interaction company

Grant
50 employees
Biotechnology, Health Care
Compare SyntheX vs A-Alpha Bio
SyntheX vs
NovaMechanics Ltd
NovaMechanics Ltd Cyprus

Cheminformatics Nanoinformatics Isalos Analytics Platform Enalos Cloud Platform

21 employees
Analytics, Biotechnology
Also compare with: SyntheX vs C4 Therapeutics, Inc. C4 Therapeutics, Inc. SyntheX vs Tierra Biosciences Tierra Biosciences

FAQ About SyntheX

Targeting the undruggable with synthetic biology-based drug discovery platforms
SyntheX was founded in 2016.
SyntheX is headquartered in San Francisco, United States.
SyntheX operates in the following industries: Biotechnology, Health and Wellness, Life Sciences, Pharmaceutical.
SyntheX has approximately 26 employees.
SyntheX has completed 6 funding rounds, raising a total of $11.58M. The latest funding stage is Series Unknown.
Top alternatives and competitors to SyntheX include TRIANA Biomedicines, A-Alpha Bio, NovaMechanics Ltd, Machine Bio, C4 Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SyntheX and TRIANA Biomedicines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors SyntheX and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy